Scarica l'app Stockscreener
40.49
1.96%
-0.81
Dopo l'orario di chiusura:
40.49
Sionna Therapeutics Inc Borsa (SION) Ultime notizie
Aberdeen Group plc Sells 110,587 Shares of Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics Executive Sells Shares - Intellectia AI
Sionna Therapeutics CLO Divests All Direct Stock Holdings in March 2026News and Statistics - IndexBox
Sionna Therapeutics (NASDAQ:SION) Trading 8.8% HigherTime to Buy? - MarketBeat
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story - Yahoo Finance
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story - The Motley Fool
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? - aol.com
Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
SION Forecast, Price Target & Analyst Ratings | SIONNA THERAPEUTICS INC (NASDAQ:SION) - ChartMill
Setup Watch: Is Sionna Therapeutics Inc currently under institutional pressureTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
SION Technical Analysis | Trend, Signals & Chart Patterns | SIONNA THERAPEUTICS INC (NASDAQ:SION) - ChartMill
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Up 3.8%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Lowers Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - AOL.com
Superstring Capital Invests in Sionna Therapeutics: Q4 2025 Filing DetailsNews and Statistics - IndexBox
'This is one of your classic, binary biotech stocks': Baral on Sionna Therapeutics - BNN Bloomberg
This investor offloaded $5 million worth of a biotech stock that surged 118% over the past year, yet there are still reasons to believe they remain optimistic about its future performance. - Bitget
Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Health Catalyst (HCAT) - The Globe and Mail
Sionna Therapeutics, Inc. $SION Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
SION: Advancing NBD1 stabilizers for cystic fibrosis with pivotal data expected by mid-2026 - TradingView
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Loss Report: Is now the right time to enter Sionna Therapeutics IncMarket Risk Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sionna Therapeutics chief legal officer sells shares for $347,018 By Investing.com - Investing.com Australia
Sionna Therapeutics chief legal officer sells shares for $347,018 - Investing.com
Sionna Therapeutics (SION) CLO trades 10,250 shares in Form 4 filing - Stock Titan
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
[144] Sionna Therapeutics, Inc. SEC Filing - Stock Titan
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Earnings Flash (SION) Sionna Therapeutics Posts Q4 Net Loss $0.46 a Share, vs. FactSet Est of $0.55 Loss - marketscreener.com
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):